CP-AU-007-01: A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL 2R Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer

Principal Investigator

Jose Lutzky

Enrollment Status

Not Accepting

Clinical Trial ID

Institutional Protocol # 20250742

Clinical Trial Summary

A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL 2R Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer

Phase

Phase I/II

Funding Agency/Sponsor

Industrial

Disease

Cutaneous Malignancies

Contact Information

Phone Number 305-243-2647